Published in Clin Exp Immunol on July 07, 2015
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 23.92
Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem (1982) 16.71
Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med (2010) 6.35
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol (2006) 4.82
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol (2001) 4.49
Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med (2012) 4.45
Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol (2000) 4.32
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care (2007) 3.80
Animal models of sepsis: setting the stage. Nat Rev Drug Discov (2005) 3.63
Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol (2000) 3.58
Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg (1992) 2.96
Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest (2009) 2.71
Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med (1997) 2.00
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73
Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med (1999) 1.71
Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res (1988) 1.60
Incidence and impact of organ dysfunctions associated with sepsis. Chest (2005) 1.58
Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int (2006) 1.46
Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest (1992) 1.36
Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology (2003) 1.35
Isoflurane improves survival and protects against renal and hepatic injury in murine septic peritonitis. Shock (2007) 1.32
A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg (2008) 1.28
Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol (2008) 1.28
Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology (2009) 1.22
CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care (2006) 1.12
Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol (2013) 1.08
Volatile anesthetics improve survival after cecal ligation and puncture. Anesthesiology (2013) 1.05
Nuclear factor kappaB and anesthetic preconditioning during myocardial ischemia-reperfusion. Anesthesiology (2004) 0.96
Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury. Anesthesiology (2009) 0.95
Emulsified intravenous versus evaporated inhaled isoflurane for heart protection: old wine in a new bottle or true innovation? Anesth Analg (2008) 0.93
Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol (2011) 0.91
Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology (2004) 0.84
Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. Anesthesiology (1995) 0.80
Intravenous application of a primary sevoflurane metabolite improves outcome in murine septic peritonitis: first results. PLoS One (2013) 0.77
Conditioning of immune response by anesthetics. Ann N Y Acad Sci (1992) 0.77
Sleeping to survive?: The impact of volatile anesthetics on mortality in sepsis. Anesthesiology (2013) 0.76